"Despite higher overall treatment costs, diabetes and weight loss patients on second-generation GLP-1 medications experience meaningfully slower medical cost growth compared to matched non-users -- though maximizing this benefit hinges heavily on therapy adherence ... Diabetes patients using GLP-1s demonstrated a six percentage point improvement in medical cost growth relative to non-users over 12 to 30 months, while weight loss users showed three percentage point improvements over an 12 to 18-month window.... [U]sers maintaining at least 80% adherence to therapy nearly doubled these gains."  MORE >>